Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897641 | 1.00 | MAOB (0.42) | MAOBPAOXDAOHRH3SLC6A4 | |
| SCHEMBL23919485 | 0.87 | MAOB (0.41) | MAOBDAOSLC2A1KDM1ASIGMAR1 | |
| SCHEMBL26381190 | 0.87 | PAOX (0.36) | PAOXKDM1ASIGMAR1KDM4EMEN1 | |
| SCHEMBL20850613 | 0.86 | MAOB (0.40) | MAOBDAOHRH3SLC6A4SLC2A1 | |
| SCHEMBL24309020 | 0.86 | MAOB (0.40) | MAOBDAOHRH3SLC2A1KDM1A | |
| SCHEMBL22337368 | 0.84 | MAOB (0.39) | MAOBDAOHRH3SLC2A1KDM1A | |
| SCHEMBL23489955 | 0.84 | MAOB (0.39) | MAOBDAOSLC2A1KDM1AMAOA | |
| SCHEMBL23132687 | 0.84 | MC4R (0.36) | MAOBDAOHRH3KDM1AKDM4E | |
| SCHEMBL8975798 | 0.82 | MAOB (0.40) | MAOBHRH3KDM4EMEN1KMT2A | |
| SCHEMBL25700799 | 0.82 | KDM4E (0.40) | PAOXKDM1ASIGMAR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-10-14 | — | — | US | disclosed |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-10-22 | — | — | US | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | MAOB 4365/4885PAOX 1632/4885DAO 3167/4885 |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | MAPK1, MAPK8, MAPK4 | MAOB 4543/4885PAOX 1461/4885DAO 3236/4885 |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | MAOB 4543/4885PAOX 1461/4885DAO 3236/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | MAOB 129/4885PAOX 2071/4885DAO 1164/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | MAOB 4543/4885PAOX 1461/4885DAO 3236/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | MAOB 2073/4885PAOX 2103/4885DAO 3310/4885 |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | MAOB 4543/4885PAOX 1461/4885DAO 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.